Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo
1. 请及时下载文件确认是否正确, 系统将在 2026-02-17 11:04:09 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: DOI: 10.1093/ejendo/lvaf043
其他信息:
G Ravel, X Gaume, C Berardet…
European Journal of …, 2025
academic.oup.com
Objective Acromegaly is an endocrine disorder caused by the hypersecretion of growth hormone (GH) by a benign tumor of the pituitary that leads to insulin-like growth factor-1 (IGF1) overproduction. In most patients, somatostatin analogs (SSAs), the current first-line medical therapy for acromegaly, do not normalize IGF1 levels. This study aims to investigate the pre-clinical efficacy of ALXN2420, a novel, small peptide antagonist of the growth hormone receptor (GHR), being developed as a combination therapy to SSAs to further …
